Pharmafile Logo

News and Press Releases

Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025

Valiltramiprosate Demonstrates Potential as the First Oral Disease-Modifying Agent to Slow Alzheimer’s Pathology, Indicated by Both Clinical and Volumetric MRI Data Nine Posters Showcase Consistent Benefits of Oral Valiltramiprosate in...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 19, 2025

Alzheon
111 Speen Street, Suite 306 Framingham, MA 01701

ONWARD Medical Receives FDA 510(k) Clearance Expanding ARC-EX System Indication for Home Use

US FDA clearance now allows use of the ARC-EX System both in clinics and homes ARC-EX is the first and only FDA-cleared technology demonstrated to improve hand strength and sensation...

Category: Biotechnology, Other, Pharmaceutical
Posted: November 17, 2025

ONWARD Medical
investors@onwd.com
Schimmelt 2. 5656 AE, Eindhoven, the Netherlands

Thermo Fisher Scientific Showcases Enhanced Accelerator Drug Development Capabilities and OpenAI Strategic Collaboration at CPHI Frankfurt 2025

Company highlights its global expertise and new and expanded capabilities to help biopharma and biotech customers solve global health challenges 27 October 2025 -- Frankfurt, Germany -- Thermo Fisher Scientific...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 27, 2025

Thermo Fisher Scientific
168 Third Avenue Waltham, MA 02451

Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions

20 October 2025 -- Valby, Denmark -- H. Lundbeck A/S and Contera Pharma today announced a strategic research collaboration aiming to accelerate the discovery and development of innovative oligonucleotide-based medicines...

Category: Biotechnology, Drug Discovery, Logistics, Other, Pharmaceutical
Posted: October 20, 2025

Lundbeck
Iveco House Station Road Watford Hertfordshire WD17 1ET

ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating ARC-EX Adoption in the United States

13 October 2025 -- EINDHOVEN, the Netherlands -- ONWARD Medical N.V., the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI)...

Category: Drug Discovery, Other, Pharmaceutical
Posted: October 13, 2025

ONWARD Medical
investors@onwd.com
Schimmelt 2. 5656 AE, Eindhoven, the Netherlands

CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Editing Platform

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile The AATD program, CTX460, is the first investigational candidate to emerge from the SyNTase editing platform...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 10, 2025

CRISPR Therapeutics
info@crisprtx.com
105 West First Street South Boston, MA 02127 617-315-4600

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Series A led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments 8 October 2025 -- New York, New York...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025

Nilo Therapeutics
info@nilotx.com

Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination

Companies sign definitive agreement following previously announced binding term sheet Transaction to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Combined company to be renamed MindMaze Therapeutics Holding...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025

Relief Therapeutics
contact@relieftherapeutics.com
Avenue de Sécheron 15 1202 Geneva Switzerland

Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA

6 October 2025 -- London, UK -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical leader, have signed exclusive licensing agreements...

Category: Logistics, Other, Pharmaceutical
Posted: October 6, 2025

Hikma Pharmaceuticals
1 New Burlington Place, London, W1S 2HR

Rezon Bio launches as a European biologics CDMO combining cost efficiency and digital innovation.

New brand with proven track record – EMA and FDA-audited mirrored-capability sites in Poland provide an accelerated path from development to commercialization 29 September 2025 -- Gdańsk, Poland -- Rezon...

Category: BioManufacturing, Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: September 29, 2025

Rezon Bio
office@rezonbio.com
Trzy Lipy 3, Building A 80-172 Gdansk, Poland

Chiesi Completes Clinical Development Program for Carbon-Minimal Pressurized Metered-Dose Inhalers (pMDIs), Paving the Way for Regulatory Submissions

Successfully completed the TRECOS Phase III study, supporting the long-term safety of Chiesi’s carbon minimal pressurized metered dose inhaler (pMDI) platform Aiming to become the first pharmaceutical company to transition...

Category: Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: September 26, 2025

Chiesi
info@chiesi.uk.com
333 Styal Road Manchester M22 5LG United Kingdom

eXmoor Pharma and Siam Bioscience form strategic partnership to establish leading Cell and Gene Therapy services in Southeast Asia

23 September 2025 -- Bristol, UK and Bangkok, Thailand -- eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Siam Bioscience, a leading biopharmaceutical company...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: September 23, 2025

eXmoor Pharma
info@exmoorpharma.com
Britannia Road, Patchway, Bristol, BS34 5TA

Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease

RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: September 3, 2025

Resolution Therapeutics
contact@resolution-tx.com
Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU

Celltrion opens new UK headquarters in Uxbridge, UK

New office located in the heart of Uxbridge underscores Celltrion’s long-term business commitment in the UK 17 June 2025 -- London, UK -- Celltrion UK has officially opened its new...

Category: Clinical Trials, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: June 17, 2025

Celltrion
23, Academy-ro, Yeonsu-gu, Incheon, Republic of Korea

iOnctura commences randomized Phase I/II study in non-small cell lung cancer

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 8, 2025

iOnctura
enquiries@ionctura.com
Campus Biotech Innovation Park Avenue Sécheron 15
 1202 Genève
 Switzerland